ROIV
Roivant Sciences Ltd.
Key Financials
Revenue
$8.3M
↓ 71.6%
Operating Income
$-515068000
↑ 48.7%
Net Income
$-299771000
↓ 74.3%
Total Assets
$5.7B
↑ 5.0%
Total Liabilities
$416.3M
↑ 66.7%
EPS (Diluted)
$-0.54
↓ 125.0%
Shareholders' Equity
$4.5B
↓ 3.4%
Cash & Equivalents
$1.4B
↓ 47.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 4 | 7/29/2026 | View on SEC |
| ARS | 7/29/2026 | View on SEC |
| DEFA14A | 7/29/2026 | View on SEC |
| DEF 14A | 7/29/2026 | View on SEC |
| 144 | 7/27/2026 | View on SEC |
| 4 | 7/21/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ROIV |
| Company Name | Roivant Sciences Ltd. |
| CIK | 1635088 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0331 |
| State of Incorporation | D0 |
| Phone | 441-295-5950 |